Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 74

Similar articles for PubMed (Select 19922681)

1.

Quantifying the treatment efficacy of reverse transcriptase inhibitors: new analyses of clinical data based on within-host modeling.

Breban R, Napravnik S, Kahn J, Blower S.

BMC Public Health. 2009 Nov 18;9 Suppl 1:S11. doi: 10.1186/1471-2458-9-S1-S11.

2.
3.

Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy.

Mocroft A, Phillips AN, Ledergerber B, Smith C, Bogner JR, Lacombe K, Wiercinska-Drapalo A, Reiss P, Kirk O, Lundgren JD; EuroSIDA Study Group.

Antivir Ther. 2010;15(4):563-70. doi: 10.3851/IMP1559.

PMID:
20587849
4.

Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy.

Staszewski S, Miller V, Sabin C, Schlecht C, Gute P, Stamm S, Leder T, Berger A, Weidemann E, Hill A, Phillips A.

AIDS. 1999 May 28;13(8):951-6.

PMID:
10371176
5.

Immunologic effects of combined protease inhibitor and reverse transcriptase inhibitor therapy in previously treated chronic HIV-1 infection.

Giorgi JV, Majchrowicz MA, Johnson TD, Hultin P, Matud J, Detels R.

AIDS. 1998 Oct 1;12(14):1833-44.

PMID:
9792384
6.

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for Treatment of HIV.

Ann Intern Med. 2002 Sep 3;137(5 Pt 2):381-433.

PMID:
12617573
7.

A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.

Idoko JA, Akinsete L, Abalaka AD, Keshinro LB, Dutse L, Onyenekwe B, Lhekwaba A, Njoku OS, Kehinde MO, Wambebe CO.

West Afr J Med. 2002 Apr-Jun;21(2):83-6.

PMID:
12403023
8.

Dynamics of HIV-1 viral load rebound among patients with previous suppression of viral replication.

Ioannidis JP, Havlir DV, Tebas P, Hirsch MS, Collier AC, Richman DD.

AIDS. 2000 Jul 28;14(11):1481-8.

PMID:
10983634
9.

Intensification of stable background therapy with abacavir in antiretroviral therapy experienced patients: 48-week data from a randomized, double-blind trial.

Katlama C, Clotet B, Plettenberg A, Jost J, Arasteh K, Bernasconi E, Jeantils V, Cutrell A, Stone C, Purdon S; CNA3002 European Study Team.

HIV Med. 2001 Jan;2(1):27-34.

PMID:
11737373
11.

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV.

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for the Treatment of HIV.

MMWR Recomm Rep. 2002 May 17;51(RR-7):1-55.

12.

Combination antiretroviral therapy without a nucleoside reverse transcriptase inhibitor: experience from 334 patients in three cohorts.

Calmy A, Petoumenos K, Lewden C, Law M, Bocquentin F, Hesse K, Cooper D, Carr A, Bonnet F; Aquitaine Cohort, Australian HIV Observational Database and St Vincent's Hospital Cohort study groups.

HIV Med. 2007 Apr;8(3):171-80.

PMID:
17461861
13.

Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.

[No authors listed]

Prescrire Int. 2004 Aug;13(72):144-50.

PMID:
15532140
14.
15.

Viral load trend in HIV-1 seropositive patients with different CD4 cell counts before starting HAART.

Re MC, Ramazzotti E, Manfredi R, Furlini G, Vignoli M, Maldini C, Borderi M, La Placa M.

J Clin Virol. 2000 Jun;17(1):5-11.

PMID:
10814933
16.

Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy.

Kaufmann GR, Bloch M, Zaunders JJ, Smith D, Cooper DA.

AIDS. 2000 May 26;14(8):959-69.

PMID:
10853977
17.

Predictive factors influencing peak viral load drop in response to nucleoside reverse transcriptase inhibitors in antiretroviral-naive HIV-1-infected patients.

Vidal C, García F, Gatell JM, Leal M, Clotet B, Pumarola T, Miró JM, Mallolas J, Ruiz L, Cruceta A, Tortajada C.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Sep 1;19(1):55-60.

PMID:
9732070
18.

Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia.

Mocroft A, Phillips AN, Ledergerber B, Katlama C, Chiesi A, Goebel FD, Knysz B, Antunes F, Reiss P, Lundgren JD.

AIDS. 2006 May 12;20(8):1141-50.

PMID:
16691065
19.
20.

"Discordant" increases in CD4 cell count relative to plasma viral load in a closely followed cohort of patients initiating antiretroviral therapy.

Wood E, Hogg RS, Yip B, Tyndall MW, Sherlock CH, Harrigan RP, O'Shaughnessy MV, Montaner JS.

J Acquir Immune Defic Syndr. 2002 Jun 1;30(2):159-66.

PMID:
12045678
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk